Arrivent Biopharma Inc (AVBP) — 13F Filings Explorer (Q2 2026)

AVBP ranks #3534 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AVBP is a top-conviction position for General Catalyst Group Management, LLC — at 27.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in AVBP belongs to Montanova Capital, LLC, but the position matters far more to General Catalyst Group Management, LLC, who has 27.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Montanova Capital, LLC has added to its AVBP position for two straight quarters, increasing it by $74.3M to reach $156.9M today.

Squarepoint Ops LLC has trimmed its AVBP position for two straight quarters, cutting it by $3.1M while still holding $609.5K.

AVBP is up 1.2% today, and institutions have been net buyers of $224.4M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AVBP reported a net loss of $166.3M in its latest fiscal year.

• Not yet profitable — net loss of $166.3M in the latest fiscal year
• Net income declined year over year, from -$80.5M to -$166.3M
• Operating cash flow was negative, using $160.6M in cash
• Current ratio of 12.83x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.08x equity — within a conventional range